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Abstract
Background: Relapses and rehospitalisations are common after acute inpatient treatment in depressive disorders.
Interventions for stabilising treatment outcomes are urgently needed. Psychoeducational group interventions for
relatives were shown to be suitable for improving the course of disease in schizophrenia and bipolar disorders.
A small Japanese monocentre randomised controlled trial also showed promising results for depressive disorders.
However, the evidence regarding psychoeducation for relatives of patients with depressive disorders is unclear.
Methods/Design: The study is conducted as a two-arm multisite randomised controlled trial to evaluate the
incremental effect of a brief psychoeducational group intervention for relatives as a maintenance treatment on the
course of disease compared to treatment as usual. Primary outcome is the estimated number of depression-free-days
in patients within one year after discharge from inpatient treatment. 180 patients diagnosed with unipolar depressive
disorders as well as one key relative per patient will be included during inpatient treatment and randomly allocated to
the conditions at discharge. In the intervention group, relatives will participate in a brief psychoeducational group
intervention following the patient’s discharge. The intervention consists of four group sessions lasting 90 to 120 min
each. Every group session contains informational parts as well as structured training in problem-solving. In
both study conditions, patients will receive treatment as usual. Patients as well as relatives will be surveyed
by means of questionnaires at discharge and three, six, nine and twelve months after discharge. In addition
to the primary outcome, several patient-related and relative-related secondary outcomes will be considered
and health economics will be investigated.
Discussion: Our study will provide evidence on the incremental effect of a brief psychoeducational intervention for
relatives as a maintenance treatment after inpatient depression treatment. Positive results may have a major impact on
health care for depression.
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Background
Relapses and rehospitalisations are common in depressive
disorders [1–3], although high pre-post effects have been
shown for inpatient depression treatment in routine care
[4], and a pharmacotherapeutic and/or psychotherapeutic
maintenance therapy can reduce the probability of re-
lapses [5]. Interventions for stabilising positive outcomes
of depression treatment are therefore urgently needed. For
other mental disorders, psychoeducation for relatives has
been shown to be suitable for improving patient-relevant
outcomes, e.g., relapse, rehospitalisation or employment
rate [6–10]. These interventions focus on the information
needs of relatives (e.g., [11–13]) as well as on reciprocal
interactions between illness-related burden and high
expressed emotion in relatives regarding relapses in
patients (e.g., [14–16]). For depressive disorders too, the
efficacy of a brief psychoeducational group intervention
for relatives (PGIR) was initially investigated regarding the
relapse rate of patients after discharge from inpatient
treatment in a first Japanese randomised controlled trial
conducted by Shimazu et al. [17]. Patients of both study
conditions were treated fortnightly, with the consultation
including an evaluation of depressive symptoms and psy-
chopharmacological and psychotherapeutic treatment. In
the intervention group, the relatives took part in a PGIR,
which consisted of four group sessions of about 90 to
120 minutes on a fortnightly basis, addressing “epidemi-
ology and causes”, “symptoms”, “treatment and course”
and “coping with the patient” as well as group discussions
for problem-solving. Relatives participating in the control
group did not receive any intervention. The relapse rate in
the intervention group was about 8 % within nine months
after discharge, in contrast to 50 % in the control group.
The study revealed a statistically and clinically significant
incremental effect to the psychiatric maintenance treat-
ment. However, in view of differences in health care sys-
tems [18] as well as cultural differences, e.g., regarding
beliefs about mental illnesses or denotation of symptoms
[19, 20], the intervention and the results of the study can-
not be directly transferred to Western countries. More-
over, the study was monocentric, with only a small sample
size (N = 57). As small monocentre trials tend to show
higher effect sizes, and results are statistically more uncer-
tain than in multicentre trials with a larger sample size
[21, 22], the results are further restricted. The primary
endpoint of the study was the time until relapse occurred,
which is a clinically relevant criterion. However, the phasic
course of depressive disorders is insufficiently reflected by
this criterion. Despite these limitations, the results of
Shimazu et al. [17] are encouraging, and are in line
with results for psychoeducation for relatives in other
mental disorders [7–10]. Therefore, the intervention
of Shimazu et al. [17] was culturally adapted [23]. As
randomised controlled multicentre trials are lacking,
and the evidence on the effects of PGIR as a maintenance
treatment after inpatient depression treatment is unclear,
further research is required to close this evidence gap.
Objectives
The aim of our study is to evaluate the incremental effect
of a short PGIR as a maintenance treatment after in-
patient depression treatment in improving the course of
illness in patients compared to treatment as usual (TAU).
We hypothesise that PGIR is more effective in improving
the course of illness than TAU alone. Additionally, we aim
to assess secondary outcomes on the patient and relative
level as well as health economics on a societal level.
Methods/Design
Study design
The effects of a brief PGIR as a maintenance treatment
after inpatient depression treatment will be investigated
by means of a two-arm parallel-group randomised con-
trolled multicentre trial using five measurements on the
patient and on the relative level within one year after
discharge of the patient (T0 = at discharge; T1 = 3; T2 = 6;
T3 = 9; T4 = 12 months after discharge). The following
eight study centres will be involved in the trial:
1. Department of Psychiatry and Psychotherapy,
Medical Centre – University of Freiburg (primary
study centre) combined with the Department of
Psychosomatic Medicine and Psychotherapy,
Medical Centre for Psychiatry Emmendingen;
2. Department of Psychiatry and Psychotherapy,
University Medical Centre Tübingen;
3. Department of Psychiatry and Psychotherapy,
University Medical Centre Leipzig;
4. Department of General Psychiatry, University
Medical Centre Heidelberg;
5. Department of Psychiatry and Psychotherapeutic
Medicine, Municipal Hospital Karlsruhe;
6. Department of Psychiatry and Psychotherapy, Vitos
Medical Centre Hadamar;
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7. Department of Psychiatry, Psychotherapy and
Psychosomatics, Vivantes Hospital am Urban Berlin;
8. Department of General Psychiatry and
Psychotherapy West, Medical Centre for Psychiatry
Weinsberg.
In order to enhance generalisability, we chose different
types of hospitals as study centres, including university
medical centres, psychiatric wards of general hospitals as
well as large psychiatric centres.
Oversight of research with human participants
The study has been approved by the Ethics Review
Committee of the University Medical Centre Freiburg
(number: 381/13) and the local Ethics Review Com-
mittees responsible for the participating sites (Ethik-
Kommission an der Medizinischen Universität Leipzig,
number: 346-14-17112014; Ethik-Kommission an der
Medizinischen Fakultät der Eberhard-Karls-Universität
und am Universitätsklinikum Tübingen, number 544/
2014BO2; Ethik-Kommission der Medizinischen Fakultät
Heidelberg, number: S-061/2015; Landesärztekammer
Baden-Württemberg, number: B-F-2014-093; Ethik-
Kommission bei der Landesärztekammer Hessen, num-
ber: MC 291/2014). Written informed consent is provided
by all study participants prior to data collection, random-
isation and intervention. To foster quality assurance and
patients’ safety, an advisory board has been implemented,
which advises the study protocol, study procedures and
realisation of the study. Additionally, trial sites will be
visited by a study monitor twice during the recruitment
period to ensure compliance with ethical principles
and the study protocol, as well as to check data quality
and accuracy.
Inclusion and exclusion criteria
The study population consists of patient-relative tan-
dems. Patients aged 18 years or older treated primarily
for a unipolar depressive disorder according to the Inter-
national Classification of Disease, 10th revision (ICD-10:
F32.xx, F33.xx) will be included. Additionally, a key rela-
tive (at least 18 years of age), who is named by the pa-
tient, has to be willing to participate in the PGIR.
Following current recommendations for psychoeduca-
tion in relatives, the relative does not have to be a family
member, but the patient does have to feel attached to
this person [24]. The participating relatives have to live
in close proximity to the respective study centre, as par-
ticipation in the PGIR has to be feasible. To ensure that
data can be gathered by questionnaires and that relatives
are able to participate in the PGIR, patients and relatives
need to be able to read and write in German. Moreover,
patients and relatives have to be able to give informed
consent. Patients will be excluded if they are diagnosed
with comorbid dementia (ICD-10: F0x.x), substance de-
pendence (ICD-10: F1x.2), schizophrenia (ICD-10: F20.x),
schizoaffective disorder (ICD-10: F25.x), bipolar disorder
(ICD-10: F31.x) or borderline personality disorder
(ICD-10: F60.31). To ensure a high external validity of our
results, no additional exclusion criteria are formulated.
Recruitment and eligibility screening
Patient-relative tandems will be recruited at the above-
mentioned sites while patients are being treated in in-
patient depression treatment. At each study centre, one
therapist, who serves as a contact person for the leading
study centre, will be responsible for the recruitment.
The recruitment procedure is identical at each site
according to the following step-by-step routine:
1. By periodically screening new admissions in routine
health records of the respective study centre,
potentially eligible patients will be identified;
2. Patients identified as potentially eligible in step one
will be informed about the study verbally as well as
through written study information;
3. If the patient is willing to participate in the trial, the
diagnosis will be confirmed using the International
Diagnostic Checklist for ICD-10 [25, 26];
4. If the patient is eligible and informed consent has
been obtained, eligibility will be screened in the
relative named by the patient and informed consent
will be obtained from the relative.
To facilitate a consistent implementation across all
sites, each procedure is described in detail in a recruit-
ment guideline. For each recruited and randomised
patient-relative tandem, an allowance of € 50 will be
paid to the recruiting staff. Recruitment will continue
until the target population has been achieved. The enrol-
ment period will extend over 12 months.
Intervention and control group
The intervention follows that of Shimazu et al. [17], but
had to be modified in some aspects in order to fit with
German conditions. The process of adaptation was based
on the results of our own studies [13, 23, 27]. The PGIR
will be conducted in a multifamily setting with one key
relative per patient and the patient being absent. Groups
will consist of three to five relatives. The PGIR consists
of four group sessions, which will be conducted on a
fortnightly basis. It will begin after discharge of the pa-
tient from inpatient depression treatment. Group ses-
sions will be held by one therapist who possesses at least
a Master’s degree or equivalent, and will last 90 to
120 min each. The intervention has two main compo-
nents: Each group session consists of about 45 min of
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provision of information, while the remaining time is
used for training problem-solving skills following the ap-
proach of Nezu et al. [28] as well as Hegel et al. [29].
The informational parts cover (1.) symptoms, epidemi-
ology, course and prognosis of depressive disorders; (2.)
support services for relatives as well as sources of per-
sonal strength and problem areas; (3.) cause of illness
and (4.) treatment of depressive disorders. Problem-
solving skill training is a brief intervention which has
shown high efficacy in several diseases both in patients
[30] and in relatives [31]. The PGIR aims to reduce care-
giver burden and expressed emotion by teaching rela-
tives how to systematically solve psychosocial problems.
To evaluate the incremental effect of the intervention,
the PGIR will be compared to treatment as usual (TAU),
which in Germany mostly consists of psychotherapeutic
and/or pharmacotherapeutic outpatient maintenance
treatment provided by psychotherapists, psychiatrists or
general practitioners [5]. In the intervention group, the
only additional intervention to TAU will be the PGIR. In
the control group, there will be no systematic informa-
tion or psychoeducational intervention offered to rela-
tives. To fit with routine care conditions, neither the
inpatient treatment before discharge nor the patient
treatment after discharge will be restricted in any way in
the intervention group or the control group.
Postulated mechanism of action
By introducing information provision and problem-
solving skills training as central components of the inter-
vention, the model of change induced by the PGIR is
expected to lead to proximal effects on relatives. These
effects are thought to influence the patient-relative dyad
and might ultimately exert a distal effect by improving
the course of illness in patients (c.f. Fig. 1).
First, it is supposed that information provision im-
proves depression literacy in relatives. In this respect,
the disease-related burden will be reduced by fostering
the understanding and handling of illness-related phe-
nomena [32]. Second, it is assumed that the problem-
solving skill training increases the problem-solving com-
petence in relatives. Accordingly, the psychosocial and
the disease-related burden will be reduced, as burden-
some day-to-day and disease-related problems – e.g.,
regarding self-care and dealing with the patient – can be
more frequently solved. As there are reciprocal interac-
tions between burden on relatives and expressed emo-
tion in relatives [14, 15], these paths are likely to reduce
expressed emotion in the patient-relative dyad.
Expressed emotion constitutes an indicator of distress in
families, taking into account criticism and emotional
overinvolvement [16, 33]. It can be distinguished into
high expressed emotion and low expressed emotion,
with the former having been shown to be a powerful
predictor of relapses in patients with depressive disor-
ders after inpatient treatment [16, 34]. Therefore, it is
supposed that positive changes on the expressed emo-
tion level might lead to reduced depressive symptoms
on the patient level.
Administration
Patient-relative tandems will be screened for eligibility
and recruited by the responsible therapists at the re-
spective study centres during inpatient treatment. In-
formed consent will be sought from all participating
patients and relatives (−T1, enrolment, c.f. Table 1). At
Fig. 1 Postulated model of change induced by the PGIR
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Table 1 Study schedule and measurements used
Study period
Enrolment Baseline Allocation Intervention Follow-up







Psychoeducational group intervention x
Adherence and competence of therapistsa/IG x
Self-rating
Patient-related
Symptom self-rating (PHQ-9, Core set) x x x x x
Rehospitalisations (FIMA, CSSRI-D) x x x x
Health care and medication consumption (FIMA, CSSRI-D) x x x x
Employment statusa x x x x x
Days of incapacity to work (DEGS) x x x x
Functional capability, activity and participation (WHODAS 2.0) x x x x x
General state of health (DEGS) x x x x x
Perceived expressed emotion (FEF) x x x
Perceived criticism (PCS) x x x




Psychosocial burden (SCL-K-9) x x x x x
Disease-related burden (IEQ-EU) x x x x x
General state of health (DEGS) x x x x x
Problem-solving competency (SPSI-R-S) x x x
Implementation of problem-solvinga x x x
Depression literacy (D-Lit)a x x
Control attributions (IPQS-R) x x x
Expressed emotion (FQ) x x x
Health care utilisation (FIMA) x x x x x
Employment statusa x x x x x
Acceptance and subjective benefit of the interventiona/IG x
Adverse Eventsa/IG x x
Demographic informationa x
-T1, during inpatient treatment; T0, at discharge from inpatient treatment; TA, allocation to intervention or control group; TInt, intervention; Follow-up: T1 = 3 months;
T2 = 6 months; T3 = 9 months; T4 = 12 months after discharge from inpatient treatment; CSSRI-D, German version of the Client Sociodemographic and Service
Receipt Inventory; DEGS, German Health Interview and Examination Survey for Adults; D-Lit, Depression Literacy Test; FEF, Questionnaire on Family Atmosphere;
FIMA, Questionnaire for Health-Related Resource Use; FQ, German version of the Family Questionnaire; IEQ-EU, German Version of the Involvement Evaluation
Questionnaire; IPQS-R, scales for control attributions of the Illness Perception Questionnaire for Schizophrenia: Relatives’ version; PCS, Perceived Criticism Scale;
PHQ-9, 9-item version of the Patient Health Questionnaire; SCL-K-9, 9-item version of the Symptom-Ckecklist-90-R; SPSI-R-S, 25-item version of the Social
Problem-Solving Inventory-Revised; WHODAS 2.0, 36-item version of the WHO Disability Assessment Schedule; aself-constructed items; IGonly administered in the
intervention group
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discharge from inpatient depression treatment, a base-
line investigation in patients will be conducted in the
respective study centres using questionnaires (T0, base-
line). At the same time, a baseline investigation in rela-
tives will be centrally provided by the leading study
centre using questionnaires sent by post (T0, baseline).
Subsequent to the baseline investigation, patient-relative
tandems will be randomly allocated to the intervention
or the control group by the leading study centre (TA,
allocation). As blinding of patient-relative tandems and
therapists is not feasible due to the nature of the inter-
vention, patient-relative tandems as well as therapists
will be informed about the allocation by the leading
study centre (TA, allocation). In the intervention group,
the intervention should begin as soon as possible after
discharge from inpatient depression treatment (TInt,
intervention). For each relative participating in the PGIR,
the therapist in charge receives an allowance of € 50
per group session. For the follow-up measurements in
patients and relatives (T1 = 3 months; T2 = 6 months;
T3 = 9 months; T4 = 12 months after discharge), postal
questionnaires provided by the leading study centre
will be used. To ensure a sufficient response rate at each
time point, patients as well as relatives will receive an
unconditional reimbursement of € 5 sent by post together
with each questionnaire. In addition, pre-stamped enve-
lopes will be added for returning the questionnaires, as
these measures are associated with a better response rate
[35]. If patients and/or relatives do not respond, they will
be reminded by post after two weeks and by telephone
after four weeks.
Primary outcome
The primary outcome is the estimated number of
depression-free-days (DFDs) on the patient level. This is
a valid and well-established measure which takes into ac-
count the course of disease and the change in symptoms
over time. Moreover, it is clinically well comprehensible
[36, 37]. In a study on the relationship between patient-
relative conflicts and long-term depression outcomes,
DFDs were proven to be change-sensitive [38]. DFDs
will be based on the Patient Health Questionnaire
(PHQ-9) [39] measured at five time points (T0 – T4)
and calculated according to Lave et al. [40] and Vannoy
et al. [41]. The PHQ-9 shows good psychometric proper-
ties [42] and is recommended by the DSM-5 and current
guidelines for unipolar depression for measuring symp-
tom severity in depressive disorders [5, 43].
Secondary outcomes
Secondary outcomes are addressed on the patient and
relative level. On a societal level, health economics are
considered as a secondary outcome. All measurement in-
struments employed to measure primary and secondary
outcomes as well as all of the measurement time points at
which they are applied are shown in Table 1.
Patient level
Rehospitalisations within the first year after discharge
from inpatient treatment, including time until rehospitali-
sation, will be considered as a secondary outcome (meas-
urement based on the FIMA [44] and the CSSRI-D [45];
time points T1 – T4). Furthermore, health care utilisation
and medication consumption will be assessed (measure-
ment based on the FIMA [44] and the CSSRI-D [45]; time
points T1 – T4). Additionally, employment status (self-
constructed items; time points T0 – T4) and days of incap-
acity to work (measurement based on the DEGS [46]; time
points T1 – T4) will be measured as secondary outcomes.
Rehospitalisation and incapacity to work are relevant out-
comes as they are objective indicators of the course of dis-
ease. As these outcomes – as well as health care utilisation
and medication consumption – are also associated with
costs, they are also important from a health economic
point of view. As psychoeducation for relatives was shown
to be effective for patients’ employment rate for other se-
vere mental disorders [6], and evidence in depression is so
far lacking, this was chosen as a secondary outcome. De-
pressive disorders can lead to impairment of functional
capability, activity and participation [47] and affects the
general state of health [48]. Therefore, these are relevant
outcomes to judge the effect of the intervention beyond
the course of disease (measured by the WHODAS 2.0 [49]
and a global item regarding the general state of health ac-
cording to the DEGS [46]; time points T0 – T4). As
expressed emotion is a powerful predictor of relapses in
depressive disorders [16], and the intervention is likely
to modify the level of expressed emotion, perceived
expressed emotion (measured by the FEF [50, 51]; time
points T0, T2, T4) as well as perceived criticism (measured
by the PCS [51, 52]; time points T0, T2, T4) are interesting
intermediate outcomes to understand how the interven-
tion works. In line with the requirement to report poten-
tial harm in patients [53], adverse events following the
intervention will be assessed in the intervention group
(self-constructed items; time points: T2, T4).
Relative level
Relatives of patients with depressive disorders experi-
ence psychosocial burden [54–56]. Therefore, psycho-
logical distress (measured by the SCL-K-9 [57]; time
points T0 – T4) and disease-related burden (measured
by the IEQ-EU [58, 59]; time points T0 – T4) were
chosen as outcomes to evaluate the effect of the inter-
vention on the relative level. As caregiver burden can
affect the health status of relatives [60], the general
health status was chosen as an additional outcome to
judge the effect of the intervention (measured by a
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global item regarding the general state of health accord-
ing to the DEGS [46]; time points: T0 – T4). As
problem-solving competency is considered as a key com-
petency for a healthy family atmosphere [61], this is con-
sidered as a secondary outcome (measured by the
SPSI-R-S [62, 63]; time points T0, T2, T4). In this re-
gard, the relatives’ implementation of the problem-
solving technique conveyed during the intervention is
seen as a mediator of the effects (self-constructed items;
time points T2, T3, T4). To capture further proximal ef-
fects of the intervention, depression literacy will be
assessed (measured by the D-Lit [64] and self-
constructed items; time points T0, T2). In addition,
control attributions will be examined (measured by
scales on control attributions from the IPQS-R [65,
66]; time points T0, T2, T4), as these can be import-
ant factors for the development of expressed emotion
[65]. Furthermore, expressed emotion will be assessed as
an intermediate outcome (measured by the FQ [67];
time points T0, T2, T4). As burden on relatives can
also be changed by using various health care services,
health care utilisation will be assessed (measurement
based on the FIMA [44]; time points T0 – T4). As
caring for a mentally ill person might have an impact
on employment activity, employment status will be
assessed (self-constructed items; time points T0 – T4).
To judge the intervention from the relatives’ point of
view, acceptance and the subjective benefit of the
PGIR will be secondary outcomes (self-constructed
items; time points T2). Following current recommen-
dations [53] and research suggesting potential negative ex-
periences of participants in group settings [68], adverse
events will be assessed in the intervention group (self-con-
structed items; time points T2, T4).
Additional parameters
Data on the following demographic parameters will be
collected via self-report questionnaire in patients and rela-
tives: age, sex, mother tongue, education, relationship and
shared household with the relative, household size, health
insurance status (self-constructed items; time point T0).
On the patient level, data on clinical characteristics will be
gathered regarding: medication, previous depressive epi-
sodes and previous inpatient treatment, duration of the
current depressive episode, first onset of the depressive
disorder and self-rated quality of the current inpatient
treatment (self-constructed items; time point T0).
Health economics
A cost-effectiveness analysis (CEA) will be undertaken
from the perspective of the statutory health insurance
and the society as a whole. A CEA expresses costs in
monetary units and outcomes in non-monetary units.
Units used for outcomes will be: (1.) DFDs, (2.)
prevented sick leave days, and (3.) prevented rehospitali-
sations. Costs of TAU and of the intervention will be
considered according to German guidelines on health
economic evaluation [69]. We will consider both direct
medical costs and indirect costs due to loss of productivity.
Standardised and validated questionnaires (c.f. Table 1) will
be used to obtain data about consumption of health re-
sources [44], which will be monetised following current
recommendations [70] to illustrate direct medical costs.
The incremental cost-effectiveness ratio of the intervention
for DFDs, prevented sick leave days and prevented rehospi-
talisations will be calculated. A budget impact analysis will
be conducted along with the economic evaluation to best
inform the needs of decision makers regarding affordability
and cost-effectiveness of the intervention.
Measures taken to minimise/avoid bias
Randomisation and concealment of allocation
To control for known and unknown confounders and
thus preclude selection bias, randomisation of patient-
relative tandems will be conducted by means of a
computer-based algorithm. Randomisation lists will
adhere to a one-to-one study-group allocation ratio
and will be stratified by centres with dynamically
adaptable block sizes to prevent predictability and to
ensure a balanced proportion of participants in both
study conditions. To meet the challenges of a group
intervention, randomisation blocks will include blocks
with two, four, six, eight and ten patient-relative tan-
dems. In each block size, the proportion of patient-
relative tandems which will be allocated to the inter-
vention or the control group is balanced. Once a
study centre has recruited at least six patient-relative
tandems, randomisation will be conducted with the
appropriate block size. If a study centre has recruited
two or four more patient-relative tandems before the
first group session in the intervention group has
taken place, they can be re-randomised and added to
the PGIR and the control group. Randomisation lists
will be centrally generated by the study statistician,
who has no direct contact with clinicians or patient-
relative tandems. To ensure allocation concealment,
randomisation lists will be inaccessible to staff in-
volved in the recruitment at the respective study cen-
tres. After recruitment of at least six patient-relative
tandems (conducting the PGIR has to be feasible),
study sites will report included patient-relative tan-
dems to the leading study centre, which will report
the allocation to the study sites as well as the
patient-relative tandems. As the effect of the interven-
tion was not moderated by any investigated variable
in the study by Shimazu et al. [17], stratification for
clinical characteristics will not be considered. How-
ever, central clinical variables (e.g., number of
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depressive episodes, duration of the current episode)
will be gathered and their effects will be investigated
in additional sensitivity analyses.
Documentation of recruitment
The recruitment of the study sample will be documented
in detail in order to judge the representativeness of
included patients compared to the basic population of in-
patients in depression treatment in the included study
sites. Basic socio-demographic data and specific reasons
for refusal of study participation of all screened patients
and relatives, as well as exclusions of screened patients
due to the above-mentioned exclusion criteria, will be
closely documented. Therefore, a standardised operating
protocol regarding the process of recruitment and inform-
ing patients as well as relatives has been developed.
Blinding
Due to the nature of the intervention, blinding of thera-
pists and patient-relative tandems is not feasible. The
primary outcome will be analysed by the study statisti-
cian, who will be blinded to the allocation of patients.
Control of intervention adherence
The intervention will be manualised and all related ma-
terials (e.g., slides, handouts) are standardised and will
be provided by the leading study centre. Additionally,
therapists will be trained in conducting the intervention
within an intensive workshop to ensure process quality
and standardisation of the intervention. Training success
will be verified by using simulated therapy situations in
the style of the Objective Structured Clinical Examination
(OSCE). Only staff reaching a previously defined standard
will be authorised to conduct the intervention within this
trial. To further ensure the integrity of the intervention,
the leading study centre will provide supervision as
well as peer consultation via telephone or video con-
ference. Finally, group sessions will be audiotaped and
rated using self-developed scales [71] to judge the
adherence and competence of therapists (TInt, inter-
vention, c.f. Table 1).
Control of treatment-related confounders
As the intervention is compared to TAU, and the treat-
ment of the patient is not restricted in any way in either
condition, different types of treatment received by the
patients might influence the effects. Therefore, data on
treatment received after discharge will be gathered on
both the patient and the relative level (c.f. Table 1) and
their effects will be investigated using sensitivity analyses.
Statistical methods
Analyses
The primary outcome, i.e., estimated DFDs one year
after discharge from inpatient depression treatment, will
be analysed by means of an analysis of covariance
(ANCOVA) (independent variables: intervention, study
centre; dependent variable: DFDs; covariate: severity of
depressive symptoms at baseline) comparing the number
of DFDs one year after discharge from inpatient depres-
sion treatment between the intervention and the control
group. The primary analysis will be performed according
to the intention-to-treat principle including all rando-
mised patients. Multiple imputations will be used to
account for missing data. Analyses with an alternative
method of dealing with missing data and using available
data will only be performed as sensitivity analyses in
order to test the robustness of the findings. Secondary
interval-scaled outcomes will be tested using t-tests and
analyses of covariance (ANCOVA, if baseline measure-
ment of the outcome is available). Dichotomous outcomes
will be analysed using Fisher’s exact test, chi-square test
(depending on expected cell frequencies), or logistic re-
gression (if covariates are present). To ensure the inter-
pretability of the results, each inferential statistical analysis
will be accompanied by descriptive analysis. Differences in
time until rehospitalisation will be analysed using Cox
regression. For parameters in which the variance cannot
be calculated analytically (e.g., cost-effectiveness), boot-
strap methods will be used. Longitudinal analyses will be
performed using general (interval-scaled outcome) or gen-
eralised (binary or ordered categorical outcome) linear
mixed models. For the primary confirmatory analysis, a
result with a type-I error under 5 % (p < .05) will be con-
sidered as statistically significant. Every additional analysis
is seen as exploratory. Accordingly, a correction of the
type-I error inflation will not be applied.
Sample size calculation
The effect of the intervention in the study by Shimazu et
al. [17] corresponds to an odds ratio of 0.09 (IG: 8 vs.
CG: 50 % relapses), equivalent to a Cohen’s d of 1.33,
which can be considered as a very large effect. However,
the sample size was comparatively small, consisting of
only 57 patient-relative tandems. Furthermore, there are
some major differences to our study. First, the interven-
tion in our study will be conducted by different thera-
pists at several study sites. Second, our study is closer to
routine conditions. Therefore, our study population will
be more heterogeneous than in the study by Shimazu et
al. [17]. A sample size of 128 patient-relative tandems
one year after discharge (T4) is sufficient to detect a
moderate effect of Cohen’s d = 0.50 (Cohen’s f = 0.25)
with a power of 80 % by analysing the primary outcome
via ANCOVA. In the study by Shimazu et al. [17], the
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dropout rate was about 5 %. As our study will be
conducted under routine conditions, we estimate a
conservative dropout rate of 10 % (N = 18) for the
time of the intervention and a further 20 % lost to
follow-up (N = 32). To reach a sample size of 128 patients
under consideration of a total dropout rate of 30 %, a total
of 180 patient-relative tandems shall be randomised.
Discussion
Our study will provide information on the effects of PGIR
as a maintenance treatment after inpatient depression
treatment on central patient-related as well as relative-
related outcomes, such as course of disease and social
functioning in patients, as well as caregiver burden and
expressed emotion in relatives. The PGIR approach evalu-
ated within this trial faired very well in one small mono-
centre trial with a small sample size [17] but has never
been evaluated within a multicentre trial. This is im-
portant, as small studies tend to overestimate effect
sizes [21, 22]. The confirmation in a multisite study is
therefore required. The brief intervention of our study is
highly suitable for routine conditions regarding psychoe-
ducation for relatives of patients in inpatient depression
treatment [27]. The results of our study will be important,
as they will close an evidence gap and can therefore clarify
recommendations in current guidelines [5] and eventually
foster the provision of PGIR as a sensible addition to
depression treatment.
Potential limitations of our study include the fact that
blinding of patients and relatives as well as therapists is
not feasible. Furthermore, patients will differ widely re-
garding their clinical characteristics due to the broad
inclusion criteria. Additionally, the group of relatives will
be heterogeneous, as we are not focusing on a specific
group of relatives, such as partners. Moreover, treatment
and health care utilisation of patients and relatives will
not be restricted. These aspects might dilute the effects
of the intervention. However, this can also be seen as
strength of our study, as the study population is likely to
come close to routine conditions and hereby can ensure
a high external validity of the results. A further limitation
is that study participants have to self-administer a high
number of measurement instruments. This might hinder
the feasibility of the trial and reduce the response rate.
Relapse and rehospitalisations are major topics after
inpatient depression treatment. PGIR is a highly promising
approach to improve the course of disease in this burden-
some disorder. However, high-quality studies dealing with
PGIR as an additional intervention to stabilise outcomes
after inpatient depression treatment are largely lacking.
Trial status
Enrolment for the trial began in March 2015. At the
time of manuscript submission, participants were still
being recruited. Recruitment is expected to continue
until March 2016. Data collection is expected to con-
tinue until March 2017.
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